Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.71 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.71 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.71 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.71 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.71 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642920 | 1.00 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1643466 | 0.91 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2539835 | 0.86 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL310492 | 0.83 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1507913 | 0.80 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL310019 | 0.80 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL29392347 | 0.80 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL381851 | 0.80 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12810360 | 0.79 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL638589 | 0.79 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295417-B1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | claimed |
| EP-2408757-B1 | A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2408450-B1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2471769-A1 | Process for preparing a benzonitrile derivative | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2295417-B1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| EP-2408757-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408450-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8093276-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8044077-B2 | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2295417-A1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | Bristol-Myers Squibb Company (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205575-B1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100240719-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| WO-2010107435-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107984-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-2205575-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | PSEN1 5/4885PSEN2 8/4885APH1B 9/4885 |
| US-20100240719-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 10/4885APH1B 6/4885 |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | PSEN1 5/4885PSEN2 8/4885APH1B 9/4885 |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | PSEN1 4/4885PSEN2 9/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.